Enterprise record

Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:7ad39d22-85e1-4628-b5fa-047dae9ac718Version: public-1As of: unavailable

10 published Claims4 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 3 claims
    • Legal Name: Telomir Pharmaceuticals, Inc. · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026

  2. SEC DEF 14A 0001493152-26-035026

    sec def 14a · Source published: Jul 28, 2026 · Retrieved: Sep 13, 2026

    Supports 3 claims
    • Leadership Role: Erez Aminov: Chief Executive Officer and Chairman · Claim reviewed: Sep 30, 2026
    • Leadership Role: Andriy Mushak: Chief Financial Officer · Claim reviewed: Sep 30, 2026
    • Leadership Role: Erez Aminov: Chief Executive Officer and Chairman · Claim reviewed: Sep 30, 2026

  3. Telomir Pharmaceuticals, Inc. DEF 14A 2026-07-28

    sec proxy · Source published: Jul 28, 2026 · Retrieved: Sep 14, 2026

    Supports 3 claims
    • Leadership Role: Edward MacPherson: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Matthew Del Giudice, M.D.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Matthew Pratt Whalen: Director · Claim reviewed: Sep 30, 2026

  4. TELO 10-K executive officers

    sec filing · Source published: Mar 17, 2026 · Retrieved: May 16, 2026

    Supports 1 claim
    • Leadership Role: Alan Weichselbaum: Chief Financial Officer · Claim reviewed: Sep 30, 2026